Weighing Clinical and Patient Experience with Hereditary Pan-Cancer Panel Testing
Among patients who carried a pathogenic variant (12%), one third of these clinically relevant results were not suspected upon pretest expert assessment
Medicare Issues Favorable Decision for myPath® Melanoma
Diagnostic test drives reduction in overtreatment by providing definitive diagnosis for suspicious skin lesion biopsies
NCCN® elevates its prostate cancer germline testing reference to RECOMMENDED for all risk groups with qualification for Very Low, Low and Intermediate
The National Comprehensive Cancer Network (NCCN) recently updated its Prostate Cancer Guidelines
Medicare coverage criteria updates align with NCCN® 2019 Guideline for BRCA1/2 genetic testing
Largest published patient- and rater-blinded randomized clinical trial in pharmacogenomics for mental health demonstrates improved outcomes
Reducing the Unknown:
Publication sheds light on hereditary cancer variant reclassifications
Did you know that one possible result of genetic testing is a variant that is classified as a Variant of Uncertain Significance?
NCCN® Updates Clinical Guidelines for Breast Cancer
EndoPredict® breast cancer recurrence test earns NCCN Category 2A recommendation for both node-negative and node-positive ER+, HER2- cancer
NCCN® Releases 4th Update to Prostate Cancer Clinical Guidelines in 2018
Category 2A recommendation for tumor-based molecular assays drives appropriate patient care
NCCN® Updates Clinical Guidelines for Lynch syndrome
Recommendations include clarified criteria for evaluation of Lynch syndrome
IMPACT demonstrates improved patient outcomes in Major Depressive Disorder (MDD)
GeneSight®-guided care shows benefit among patients treated by either primary care physicians or psychiatrists
2018 ASCO Annual Meeting
Data Highlights the Value of Individualized Insight into Cancer Risk
Validated algorithm incorporated into Prolaris® test report empowers men to safely pursue active surveillance
Many men with prostate cancer needlessly suffer treatment-related side effects without a meaningful change in prognosis.
Landmark study shows GeneSight® testing led to significant improvement in mental health outcomes for patients with major depressive disorder
Findings from the largest-ever pharmacogenomics clinical study were presented at the American Psychiatric Association annual meeting earlier this month.
Clinical breakthrough for women with metastatic breast cancer
Use of PARP inhibitor in patients with BRCA1/2 mutations and HER2-negative metastatic breast cancer shows promise
NCCN® Updates Clinical Guidelines for Prostate Cancer
Guidelines now support Prolaris® in treatment decision making for patients with low- and favorable intermediate-risk prostate cancer
New data differentiate prognostic value of four multigene expression tests
An analysis of four breast prognostic tests, Oncotype DX® Breast, Prosigna®, EndoPredict®, and Breast Cancer IndexSM, and two prognostic algorithms, Clinical Treatment Score (CTS) and IHC4, was recently published in JAMA Oncology.
Myriad receives FDA approval of BRACAnalysis CDX® as companion diagnostic for Lynparza™ (olaparib)
New treatment for patients who have BRCA1/2 mutations and HER2-negative metastatic breast cancer
NCCN Clinical Guideline updates increase genetic testing access for patients with metastatic breast and prostate cancers
Revisions drive optimized treatment for patients & answers for family members
Laboratory QA process drives clinical utility of hereditary cancer testing
Recent publication shows how comprehensive quality assurance processes curtail unnecessary healthcare costs while driving clinical utility of testing
ACOG & SGO release joint statement on Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
The American College of Obstetricians and Gynecologists (ACOG) and Society of Gynecologic Oncology
Findings from SOLO2/ENGOT-Ov21 confirm efficacy of PARP inhibitor in patients with BRCA-mutated ovarian cancer
Results from trial published in Lancet Oncology
ASCO Annual Meeting delivers data showing hereditary cancer testing benefit
June 2017 | Issue 2
Presentations highlight critical results for patients managing cancer
Medicare Expands Coverage of Prolaris®
June 2017 | Issue 1
Medicare has announced expanded coverage of Prolaris, a prostate cancer prognostic biomarker test. Now Medicare patients with NCCN favorable intermediate-risk disease have coverage, in addition to very low- and low-risk patients (MolDX LCD IDs: L36350 and L37082).
Publication demonstrates significant discordance in genetic variant classifications found in public database compared to a commercial laboratory
May 2017 | Issue 2
An article published in The Oncologist in April, 2017 explores discordance among variant classifications housed in public databases when compared to a commercial testing laboratory.
Recent data demonstrate benefit of PARP inhibitors for patients with ovarian cancer
May 2017 | Issue 1
The promise of precision medicine is realized when medical care is optimized to serve the right patient at the right time with the right treatment or therapy.
Myriad announces the launch of EndoPredict®, a gene expression test for patients with breast cancer
EndoPredict provides a patient’s 10-year risk of distant recurrence. This information can be used to determine if a patient can forgo adjuvant chemotherapy. Published literature demonstrates EndoPredict’s greater prognostic value compared to first generation tests.
Applying the Center for Medical Technology Policy’s (CMTP) chain of evidence for clinical utility to Prolaris, a prognostic prostate cancer test developed by Myriad Genetic Laboratories
Genomic medicine has opened promising avenues for molecular diagnostic testing in health care.
Blue Cross Blue Shield Association drives progress for patients with breast cancer
Evidence Street™ has recently announced that EndoPredict® results in a meaningful improvement in the net health outcomes in node-negative breast cancer patients.